247 related articles for article (PubMed ID: 24119836)
1. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
King CR; Collins S; Fuller D; Wang PC; Kupelian P; Steinberg M; Katz A
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):939-45. PubMed ID: 24119836
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
4. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
Rucinska M; Kieszkowska-Grudny A; Nawrocki S
Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
[TBL] [Abstract][Full Text] [Related]
5. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
Dess RT; Jackson WC; Suy S; Soni PD; Lee JY; Abugharib AE; Zumsteg ZS; Feng FY; Hamstra DA; Collins SP; Spratt DE
Cancer; 2017 May; 123(9):1635-1642. PubMed ID: 28001303
[TBL] [Abstract][Full Text] [Related]
6. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.
Katz A; Ferrer M; Suárez JF;
Radiat Oncol; 2012 Nov; 7():194. PubMed ID: 23164305
[TBL] [Abstract][Full Text] [Related]
7. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
9. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract][Full Text] [Related]
10. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer.
Gomez CL; Xu X; Qi XS; Wang PC; Kupelian P; Steinberg M; King CR
Pract Radiat Oncol; 2015; 5(4):257-62. PubMed ID: 25749214
[TBL] [Abstract][Full Text] [Related]
13. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
[TBL] [Abstract][Full Text] [Related]
14. Potency preservation following stereotactic body radiation therapy for prostate cancer.
Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
King CR; Brooks JD; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):877-82. PubMed ID: 21300474
[TBL] [Abstract][Full Text] [Related]
16. Proctitis following stereotactic body radiation therapy for prostate cancer.
Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
[TBL] [Abstract][Full Text] [Related]
17. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
Chen LN; Suy S; Wang H; Bhagat A; Woo JA; Moures RA; Kim JS; Yung TM; Lei S; Collins BT; Kowalczyk K; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Jun; 9():148. PubMed ID: 24966110
[TBL] [Abstract][Full Text] [Related]
19. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
[TBL] [Abstract][Full Text] [Related]
20. Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Kole TP; Tong M; Wu B; Lei S; Obayomi-Davies O; Chen LN; Suy S; Dritschilo A; Yorke E; Collins SP
Acta Oncol; 2016; 55(1):52-8. PubMed ID: 25972264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]